Ken Griffin Cardiol Therapeutics Inc. Call Options Transaction History

Citadel Advisors LLC

6 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2024 Aug 14, 2024	SELL	$1.67 - $2.97 $7,181 - $12,771	-4,300 Reduced 12.76%	29,400 $59,000
Q1 2024 May 15, 2024	BUY	$0.88 - $2.06 $20,152 - $47,174	22,900 Added 212.04%	33,700 $60,000
Q4 2023 Feb 14, 2024	BUY	$0.67 - $1.0 $7,236 - $10,800	10,800 New	10,800 $9,000
Q1 2023 May 15, 2023	SELL	$0.47 - $0.81 $11,233 - $19,359	-23,900 Reduced 84.15%	4,500 $2,000
Q4 2022 Feb 14, 2023	SELL	$0.48 - $1.0 $23,904 - $49,800	-49,800 Reduced 63.68%	28,400 $14,000
Q3 2022 Nov 14, 2022	BUY	$1.02 - $1.41 $49,674 - $68,667	48,700 Added 165.08%	78,200 $81,000

5.5M

162K

7.4K

Ticker CRDL
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 61,942,500
Market Cap $120M
Description
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of cardiovascular disease (CVD). Its lead product is CardiolRx, which is in Phase II/III multi-national, randomized, double-blind, and placebo-controlled study to evaluate t...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.